For individuals who suffer from schizophrenia, activities of daily living can be impeded by uncontrolled symptoms. With the FDA approval of Invega, in late 2006, individuals suffering from schizophrenia are provided with a new cutting edge drug to relieve symptoms and approve daily living activities.
Invega, manufactured and distributed by Johnson & Johnson, provides for a relief of schizophrenia symptoms in as little as three consecutive weeks of treatment. Schizophrenia symptoms such as hallucinations, movement disorders and impaired judgment and thinking are quickly dissipated with the consecutive 15 days of Invega use.
Dosing of Invega, in the treatment of schizophrenia, is recommended at levels from three milligrams to 15 milligrams per day with 15 milligrams rarely recommended. Because Invega, in the treatment of schizophrenia, has not been tested beyond six weeks, it is unclear if the dosing of three to 15 milligrams for greater than this period is therapeutic. As a result, the psychiatrist should re-evaluate the patient to confirm the improvement in symptoms remains consistent. When symptoms do not appear to be well controlled, beyond the initial six weeks of use, weaning the schizophrenia patient should be considered with a change to a new form of treatment.
As with any FDA approved drug, Invega, in the treatment of schizophrenia, does not come without side effects. Most commonly, side effect may include insomnia, an increase in heart rate and even restlessness. While the side effects are minimal they are common and can persist over the entire course of treatment. When symptoms become more severe than mild heart rate increase, consult the psychiatrist immediately.
Patients who suffer from schizophrenia while co morbid for diabetes, obesity and heart disease should not use Invega. Invega, in the treatment of schizophrenia, can lead to an exacerbation of these conditions. Only in rare cases should the psychiatrist prescribe Invega to schizophrenia patients with these pre-existing health histories.
In addition to obesity, high blood pressure and diabetes, elderly patients who suffer from dementia or Alzheimer’s are also contraindicated in the use of Invega for the treatment of schizophrenia. In the FDA approval of Invega, the recommendation was placed to avoid providing Invega to dementia prone patients due to the potential implication for increased risk of death.
As with any medication used to treatment psychological conditions, complete analysis of the mental health condition in addition to a complete physical examination should be completed to ensure the schizophrenia patient does not suffer from adverse, life impacting health reactions while using Invega. When cleared, consider using Invega for the treatment of schizophrenia.